Osteoporosis Drugs Market: By Drug Class, Gender, Type, Analysis & Forecast, 2015-2021

Osteoporosis Drugs Market: By Drug Class, Gender, Type, Analysis & Forecast, 2015-2021

Comments Off on Osteoporosis Drugs Market: By Drug Class, Gender, Type, Analysis & Forecast, 2015-2021

According to the report, the global osteoporosis drugs market was valued at approximately USD 11.20 billion in 2015 and is expected to reach approximately USD 14.30 billion by 2021, growing at a CAGR of around 4.0% between 2016 and 2021. Osteoporosis is a bone disease in which a fragile bone with an increased susceptibility to fracture. Bones that commonly fracture include the backbones, the bones of the forearm, and the hip.




According to the report, the global osteoporosis drugs market was valued at approximately USD 11.20 billion in 2015 and is expected to reach approximately USD 14.30 billion by 2021, growing at a CAGR of around 4.0% between 2016 and 2021.

Osteoporosis is a bone disease, which may be due to lower than normal peak bone mass and greater than the normal bone loss. Osteoporosis may also occur due to a number of diseases or treatments such as anorexia, hyperthyroidism, alcoholism, surgical removal of the ovaries, and kidney disease. As a result, bones become weak and may break from a fall or, in serious cases, from sneezing or minor bumps.  Until a broken bone occurs there are typically no symptoms. Osteoporosis drugs are a kind of medicine for osteoporosis, including Zoledronic Acid (Reclast or Zometa) Fosamax, Actonel, Boniva and others.

The major driving factor for the global osteoporosis market is rapidly growing the geriatric population of the world coupled with changing lifestyle is impinging bone health. Furthermore, increasing the prevalence of osteoporosis in postmenopausal women and increasing investment in drug discovery and development is further expected to fuel the market growth in the years to come. Prevalence of osteoporosis is more common with age. Around 15% of white people in their 50s and 70% of those over 80 are affected by osteoporosis diseases. However, there are several side effects of osteoporosis drugs such as irritable bowel syndrome, heartburn, nausea, and ulcers in the stomach. Thus, side effects of osteoporosis drugs are expected to hamper the market growth over the next few years. Nevertheless, increasing investment in R&D for advanced development of new drugs and classes are expected open up new growth avenues within the forecast period.

Global Osteoporosis Drug Market

The osteoporosis drugs market is segmented on the basis of different drug classes such as bisphosphonates, calcitonin, rank ligand inhibitors, parathyroid hormone therapy (PTH) and selective estrogen receptor modulators (SERMs).  Osteoporosis drugs market was dominated by the bisphosphonates segment, which accounted for significant revenue share in 2015. Bisphosphonates are commonly prescribed the drug for treatment and prevention of osteoporosis disease. Thus, this segment is expected to show strong growth in the near future. Tele-monitoring is another growing segment of this market. Parathyroid hormone therapy (PTH) was another growing segment of this market. Parathyroid hormone therapy (PTH) was another key segment and it expected to witness significant growth in the near future. Development of new drug classes such as PTH and RANK ligand inhibitors are projected to fuel the growth of osteoporosis drug market over the forecast period. Pipeline products such as odanacatib (cathepsin K inhibitor) and romosozumab are awaiting the approval and may contribute to driving the market growth in the years to come.

Based on gender, the market can be segmented into male and female. Osteoporosis is more common in female than male. The female segment accounted for the largest share in 2015. Increasing the prevalence of osteoporosis in postmenopausal women is driving the growth of the market. There are wide discrepancies between the incidence rate in women and men. Moreover, about 90% of the hip fractures occur in people over 50 years old.

North America was the largest regional market led by the U.S. and is projected to witness the highest growth within the forecast period owing to high investments in the healthcare industry, surging R&D initiatives and accessibility to the excellent infrastructure. Asia Pacific osteoporosis drugs market is expected to be the fastest-growing region in the years to come. Growth in this region will be mainly driven by factors such as rising aged population and increasing patient’s awareness pertaining to bone health. Latin America and the Middle East & Africa are also expected to experience significant growth of osteoporosis market in the years to come.

Some of the key participants in osteoporosis drug market are Novartis International AG, Eli Lilly Amgen Inc., Forteo, Novo Nordisk A/S., F. Hoffmann La Roche Ltd., and Company, Merck & Co, Inc., Actavis plc, Pfizer, Inc, and Teva Pharmaceutical Industries Ltd.  Major players are implementing sustainability strategies including product expansions, new product development and merger & acquisitions to gain the advantage over the competitors. For instance, drug maker Actavis Inc. agreed to acquire Warner Chilcott PLC for about USD5 billion in an all-stock deal aimed at enlarging Actavis’s portfolio of specialty pharmaceutical brands—and shrinking its tax burden in 2013. Pipeline drugs of Merck and Pfizer cathepsin and aprela respectively are projected to provide the growth platform for these respective companies.

  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  • Chapter 2. Executive Summary
    • 2.1. Global osteoporosis drugs market, 2015 – 2021 (USD Billion)
    • 2.2. Global osteoporosis drugs market : Snapshot
  • Chapter 3. Osteoporosis drugs – Market Dynamics
    • 3.1. Introduction
    • 3.2. Market drivers
      • 3.2.1. Global osteoporosis drugs market drivers: Impact analysis
      • 3.2.2. Increasing the prevalence of osteoporosis
    • 3.3. Market restraints
      • 3.3.1. Global osteoporosis drugs market restraints: Impact analysis
      • 3.3.2. Side effects of osteoporosis drugs
    • 3.4. Opportunities
      • 3.4.1. Advancement in Research and development
    • 3.5. Porter’s five forces analysis
      • 3.5.1. Bargaining power of suppliers
      • 3.5.2. Bargaining power of buyers
      • 3.5.3. Threat from new entrants
      • 3.5.4. Threat from new substitutes
      • 3.5.5. Degree of competition
    • 3.6. Market attractiveness analysis
      • 3.6.1. Market attractiveness analysis, by drug class segment
      • 3.6.2. Market attractiveness analysis, by gender segment
      • 3.6.3. Market attractiveness analysis, by regional segment
  • Chapter 4. Global Osteoporosis drugs Market – Competitive Landscape
    • 4.1. Company Market Share Analysis(Subject to data availability)
      • 4.1.1. Global osteoporosis drugs market: company market share, 2015
    • 4.2. Strategic Development
      • 4.2.1. Acquisitions & Mergers
      • 4.2.2. New Drug class Launch
      • 4.2.3. Agreements, Partnerships, Collaborations and Joint Ventures
      • 4.2.4. Research and Development, Drug class and Regional Expansion
    • 4.3. Product Portfolio
    • 4.4. Patent Analysis (2011-2016)
      • 4.4.1. Patent Trend
      • 4.4.2. Patent Share by company
      • 4.4.3. By Region
  • Chapter 5. Global Osteoporosis Drugs Market – Drug Class Segment Analysis
    • 5.1. Global osteoporosis drugs market: Drug class overview
      • 5.1.1. Global osteoporosis drugs market revenue share, by drug class, 2015 and 2021
    • 5.2. Bisphosphonates
      • 5.2.1. Global bisphosphonates market, 2015 – 2021(USD Billion)
    • 5.3. Electromagnetic Blood Flowmeters
      • 5.3.1. Global electromagnetic blood flowmeters market , 2015 – 2021(USD Billion)
    • 5.4. Rank Ligand Inhibitors
      • 5.4.1. Global rank ligand inhibitors market , 2015 – 2021(USD Billion)
    • 5.5. Parathyroid Hormone Therapy (PTH)
      • 5.5.1. Global parathyroid hormone therapy (PTH) market , 2015 – 2021(USD Billion)
    • 5.6. Selective Estrogen Receptor Modulators (SERMs)
      • 5.6.1. Global selective estrogen receptor modulators (SERMs) market , 2015 – 2021(USD Billion)
  • Chapter 6. Global Osteoporosis Drugs Market – Gender Segment Analysis
    • 6.1. Global osteoporosis drugs market: Gender overview
      • 6.1.1. Global osteoporosis drugs market revenue share, by gender, 2015 and 2020
    • 6.2. Male
      • 6.2.1. Global osteoporosis drugs market for male, 2015 – 2021 (USD Billion)
    • 6.3. Female
      • 6.3.1. Global osteoporosis drugs market for female, 2015 – 2021(USD Billion)
  • Chapter 7. Global Osteoporosis Drugs Market – Regional Segment Analysis
    • 7.1. Global osteoporosis drugs market: Regional overview
      • 7.1.1. Global osteoporosis drugs market revenue share, by region, 2015 and 2021
    • 7.2. North America
      • 7.2.1. North America osteoporosis drugs market revenue, by drug class, 2015 – 2021(USD Billion)
      • 7.2.2. North America osteoporosis drugs market revenue, by gender, 2015 – 2021(USD Billion)
      • 7.2.3. U.S.
        • 7.2.3.1. U.S. osteoporosis drugs market revenue, by drug class, 2015 – 2021(USD Billion)
        • 7.2.3.2. U.S. osteoporosis drugs market revenue, by gender, 2015 – 2021(USD Billion)
    • 7.3. Europe
      • 7.3.1. Europe osteoporosis drugs market revenue, by drug class, 2015 – 2021(USD Billion)
      • 7.3.2. Europe osteoporosis drugs market revenue, by gender, 2015 – 2021(USD Billion)
      • 7.3.3. Germany
        • 7.3.3.1. Germany osteoporosis drugs market revenue, by drug class, 2015 – 2021(USD Billion)
        • 7.3.3.2. Germany osteoporosis drugs market revenue, by gender, 2015 – 2021(USD Billion)
      • 7.3.4. France
        • 7.3.4.1. France osteoporosis drugs market revenue, by drug class, 2015 – 2021(USD Billion)
        • 7.3.4.2. France osteoporosis drugs market revenue, by gender, 2015 – 2021(USD Billion)
      • 7.3.5. UK
        • 7.3.5.1. UK osteoporosis drugs market revenue, by drug class, 2015 – 2021(USD Billion)
        • 7.3.5.2. UK osteoporosis drugs market revenue, by gender, 2015 – 2021(USD Billion)
    • 7.4. Asia Pacific
      • 7.4.1. Asia Pacific osteoporosis drugs market revenue, by drug class, 2015 – 2021, (USD Billion)
      • 7.4.2. Asia Pacific osteoporosis drugs market revenue, by gender, 2015 – 2021, (USD Billion)
      • 7.4.3. China
        • 7.4.3.1. China osteoporosis drugs market revenue, by drug class, 2015 – 2021(USD Billion)
        • 7.4.3.2. China osteoporosis drugs market revenue, by gender, 2015 – 2021(USD Billion)
      • 7.4.4. Japan
        • 7.4.4.1. Japan osteoporosis drugs market revenue, by drug class, 2015 – 2021(USD Billion)
        • 7.4.4.2. Japan osteoporosis drugs market revenue, by gender, 2015 – 2021(USD Billion)
      • 7.4.5. India
        • 7.4.5.1. India osteoporosis drugs market revenue, by drug class, 2015 – 2021(USD Billion)
        • 7.4.5.2. India osteoporosis drugs market revenue, by gender, 2015 – 2021(USD Billion)
    • 7.5. Latin America
      • 7.5.1. Latin America osteoporosis drugs market revenue, by drug class, 2015 – 2021(USD Billion)
      • 7.5.2. Latin America osteoporosis drugs market revenue, by gender, 2015 – 2021(USD Billion)
      • 7.5.3. Brazil
        • 7.5.3.1. Brazil osteoporosis drugs market revenue, by drug class, 2015 – 2021(USD Billion)
        • 7.5.3.2. Brazil osteoporosis drugs market revenue, by gender, 2015 – 2021 (USD Billion)
    • 7.6. Middle East and Africa
      • 7.6.1. Middle East and Africa osteoporosis drugs market revenue, by drug class, 2015 – 2021 (USD Billion)
      • 7.6.2. Middle East and Africa osteoporosis drugs market revenue, by gender, 2015 – 2021(USD Billion)
  • Chapter 8. Company Profile
    • 8.1. Novartis International AG
      • 8.1.1. Overview
      • 8.1.2. Financials
      • 8.1.3. Product portfolio
      • 8.1.4. Business strategy
      • 8.1.5. Recent developments
    • 8.2. Eli Lilly Amgen Inc
      • 8.2.1. Overview
      • 8.2.2. Financials
      • 8.2.3. Product portfolio
      • 8.2.4. Business strategy
      • 8.2.5. Recent developments
    • 8.3. Forteo
      • 8.3.1. Overview
      • 8.3.2. Financials
      • 8.3.3. Product portfolio
      • 8.3.4. Business strategy
      • 8.3.5. Recent developments
    • 8.4. Merck & Co, Inc.
      • 8.4.1. Overview
      • 8.4.2. Financials
      • 8.4.3. Product portfolio
      • 8.4.4. Business strategy
      • 8.4.5. Recent developments
    • 8.5. Actavis plc
      • 8.5.1. Overview
      • 8.5.2. Financials
      • 8.5.3. Product portfolio
      • 8.5.4. Business strategy
      • 8.5.5. Recent developments
    • 8.6. Pfizer, Inc
      • 8.6.1. Overview
      • 8.6.2. Financials
      • 8.6.3. Product portfolio
      • 8.6.4. Business strategy
      • 8.6.5. Recent developments
    • 8.7. Teva Pharmaceutical Industries Ltd
      • 8.7.1. Overview
      • 8.7.2. Financials
      • 8.7.3. Product portfolio
      • 8.7.4. Business strategy
      • 8.7.5. Recent developments
    • 8.8. F. Hoffmann La Roche Ltd.
      • 8.8.1. Overview
      • 8.8.2. Financials
      • 8.8.3. Product portfolio
      • 8.8.4. Business strategy
      • 8.8.5. Recent developments

List of Figures

1. Market research process
2. Market research methodology
3. Global osteoporosis drugs market revenue, 2015 – 2021(USD Billion)
4. Porter’s five forces analysis
5. Osteoporosis drugs: Market attractiveness analysis, by drug class segment
6. Osteoporosis drugs: Market attractiveness analysis, by gender segment
7. Osteoporosis drugs: Market attractiveness analysis, by regional segment
8. Company market share analysis, 2015
9. Patent trend between 2011 -2016
10. Patent share by company between 2011 – 2016
11. Patent share by region between 2011 – 2016
12. Global osteoporosis drugs market revenue share by drug class, 2015 and 2021
13. Global bisphosphonates market, 2015 – 2021 (USD Billion)
14. Global electromagnetic blood flowmetersmarket, 2015 – 2021(USD Billion)
15. Global rank ligand inhibitors market, 2015 – 2021 (USD Billion)
16. Global osteoporosis drugs market revenue share by gender, 2015 and 2021
17. Global osteoporosis drugs market for male, 2015 – 2021, (USD Billion)
18. Global osteoporosis drugs market for female, 2015 – 2021, (USD Billion)
19. Global osteoporosis drugs market for dermatology, 2015 – 2021, (USD Billion)
20. Global osteoporosis drugs market for gastroenterology, 2015 – 2021, (USD Billion)
21. Global osteoporosis drugs market for other gender, 2015 – 2021, (USD Billion)


List of Tables

1. Osteoporosis drugs market: Market snapshot
2. Drivers of global osteoporosis drugs market: Impact analysis
3. Restraints of global osteoporosis drugs market: Impact analysis
4. North America osteoporosis drugs market revenue, by drug class, 2015 – 2021(USD Billion)
5. North America osteoporosis drugs market revenue, by gender, 2015 – 2021(USD Billion)
6. U.S. osteoporosis drugs market revenue, by drug class, 2015 – 2021(USD Billion)
7. U.S. osteoporosis drugs market revenue, by gender, 2015 – 2021(USD Billion)
8. Germany osteoporosis drugs market revenue, by drug class, 2015 – 2021(USD Billion)
9. Germany osteoporosis drugs market revenue, by gender, 2015 – 2021(USD Billion)
10. France osteoporosis drugs market revenue, by drug class, 2015 – 2021(USD Billion)
11. France osteoporosis drugs market revenue, by gender, 2015 – 2021(USD Billion)
12. UK osteoporosis drugs market revenue, by drug class, 2015 – 2021(USD Billion)
13. UK osteoporosis drugs market revenue, by gender, 2015 – 2021(USD Billion)
14. Asia Pacific osteoporosis drugs market revenue, by drug class, 2015 – 2021(USD Billion)
15. Asia Pacific osteoporosis drugs market revenue, by gender, 2015 – 2021(USD Billion)
16. China osteoporosis drugs market revenue, by drug class 2015 – 2021(USD Billion)
17. China osteoporosis drugs market revenue, by gender 2015 – 2021(USD Billion)
18. Japan osteoporosis drugs market revenue, by drug class, 2015 – 2021(USD Billion)
19. Japan osteoporosis drugs market revenue, by gender, 2015 – 2021(USD Billion)
20. India osteoporosis drugs market revenue, by drug class, 2015 – 2021(USD Billion)
21. India osteoporosis drugs market revenue, by gender, 2015 – 2021(USD Billion)
22. Latin America osteoporosis drugs market revenue, by drug class, 2015 – 2021(USD Billion)
23. Latin America osteoporosis drugs market revenue, by gender, 2015 – 2021(USD Billion)
24. Brazil osteoporosis drugs market revenue, by drug class, 2015 – 2021(USD Billion)
25. Brazil osteoporosis drugs market revenue, by gender, 2015 – 2021(USD Billion)
26. Middle East and Africa osteoporosis drugs market revenue, by drug class, 2015 – 2021(USD Billion)
27. Middle East and Africa osteoporosis drugs market revenue, by gender, 2015 – 2021(USD Billion)

* Indicates required field.

Your Name*

Your Email*

Telephone Number*

Name of company*

Country Name*

How can we help you?

Prove You are Human*

captcha
Enter Capcha Image Properly



Share this Post

Related Posts

Checking...

Ouch! There was a server error.
Retry »

Sending message...

Enquiry Form

Fill in the form below and we will be in touch soon

Create Account



Log In Your Account